SPYRE THERAPEUTICS INC (SYRE)

US00773J2024 - Common Stock

33.8  -0.6 (-1.74%)

After market: 33.8 0 (0%)

News Image
15 days ago - Market News Video

SYRE Crosses Above Key Moving Average Level

News Image
16 days ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented...

News Image
25 days ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody...

News Image
2 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics to Participate in Upcoming Investor Conference

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational...

News Image
3 months ago - InvestorPlace

SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024

SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

News Image
3 months ago - BusinessInsider

SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spyre Therapeutics (NASDAQ:SYRE) just reported results for the second quarter o...

News Image
3 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept...

News Image
4 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks...

News Image
5 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
6 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
6 months ago - InvestorPlace

SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024

SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

News Image
6 months ago - BusinessInsider

SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spyre Therapeutics (NASDAQ:SYRE) just reported results for the first quarter of...

News Image
6 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin...

News Image
6 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
7 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
8 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces $180 Million Private Placement

/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody...

News Image
8 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
8 months ago - Seeking Alpha

Spyre Therapeutics GAAP EPS of -$4.05 (NASDAQ:SYRE)

Read about Spyre Therapeutics' latest financial results and find out their Q4 GAAP EPS of -$4.05 in our press release.

News Image
8 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the...

News Image
8 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
9 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
9 months ago - Seeking Alpha

Spyre Therapeutics appoints Mark C. Mckenna to its Board (NASDAQ:SYRE)

Spyre Therapeutics announces appointment of Mark C. McKenna to its Board of Directors.

News Image
9 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
9 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

News Image
10 months ago - BusinessInsider

3 Best Stocks to Buy Now,4, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a n...

News Image
10 months ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...

News Image
10 months ago - Seeking Alpha

Spyre Therapeutics to sell 12M shares for holders (NASDAQ:SYRE)

Spyre Therapeutics (SYRE) files prospectus for resale of 12M shares by selling stockholders; it does not constitute an offer to sell securities.

News Image
a year ago - Seeking Alpha

Spyre Therapeutics announces $180 million private placement (NASDAQ:SYRE)

Spyre Therapeutics announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to re

News Image
a year ago - Spyre Therapeutics, Inc.

Spyre Therapeutics Announces $180 Million Private Placement

/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...